China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced an exclusive agreement with Adimmune Corporation for the distribution of AdimFlu-S (QIS) in mainland China. AdimFlu-S (QIS) is the only imported quadrivalent seasonal influenza vaccine approved for use in individuals aged three years and older in China. The agreement also grants Clover rights to commercialize AdimFlu-S (QIS) in Bangladesh, Brazil, and the Philippines, subject to regulatory approvals, and opens the door for potential collaboration on the development of additional vaccine candidates, including next-generation influenza vaccines.
Manufacturing and Regulatory Compliance
Adimmune will manufacture AdimFlu-S (QIS) at its facility, which has been certified for good manufacturing practices (GMP) by the European Medicines Agency and the US FDA, among other regulatory bodies. This ensures the vaccine meets the highest standards of quality and safety.
Vaccine Efficacy and Approval
AdimFlu-S (QIS) is a quadrivalent split inactivated vaccine designed to prevent influenza. As a quadrivalent vaccine, it contains hemagglutinin from four influenza virus strains (two A and two B), which enhances its effectiveness regardless of which influenza B strain becomes seasonally prevalent, compared to trivalent options. The vaccine was approved by the China National Medical Products Administration in January 2022 for individuals aged three years and older.-Fineline Info & Tech
